Prosecution Insights
Prosecution Insights
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| §103 only | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WEBB, WALTER E | 1 | 46.4% | +18.7% |
| FAY, ZOHREH ALEMZADEH | 1 | 52.0% | -6.2% |
| CREWS, JARET JAMES | 1 | 43.5% | +73.8% |
| FERNANDEZ, SUSAN EMILY | 1 | 52.3% | +60.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18860409 | Microemulsion Pharmaceutical Composition For Treatment Of Disorders Of The Anterior Segment Of The Eye | WEBB, WALTER E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17796904 | XANTHAN-BASED OPHTHALMIC TOPICAL FORMULATIONS WITH A REDUCED DOSAGE REGIMEN | CREWS, JARET JAMES | 119d overdue |
| 17782207 | EYE TOPICAL COMPOSITION CONTAINING METABOLITES OF THE FERMENTATION OF LACTOBACILLUS | FERNANDEZ, SUSAN EMILY | 44d overdue |
| 18860409 | Microemulsion Pharmaceutical Composition For Treatment Of Disorders Of The Anterior Segment Of The Eye | WEBB, WALTER E | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| 1691 | 1 |
| 1651 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18860409 | Microemulsion Pharmaceutical Composition For Treatment Of Disorders Of The Anterior Segment Of The Eye | WEBB, WALTER E | — | §101§102§103§112 | Non-Final OA | — | Pending | Oct 25, 2024 |
| 17802588 | FORMULATION BASED ON POLYHEXAMETHYLENE BIGUANIDE FOR USE IN THE TREATMENT OF ACANTHAMOEBA KERATITIS AND/OR FUNGAL INFECTIONS | FAY, ZOHREH ALEMZADEH | 1617 | §103 | Non-Final OA | 24d overdue | Pending | Aug 26, 2022 |
| 17796904 | XANTHAN-BASED OPHTHALMIC TOPICAL FORMULATIONS WITH A REDUCED DOSAGE REGIMEN | CREWS, JARET JAMES | 1691 | §103 | Final Rejection | 119d overdue | Pending | Aug 02, 2022 |
| 17782207 | EYE TOPICAL COMPOSITION CONTAINING METABOLITES OF THE FERMENTATION OF LACTOBACILLUS | FERNANDEZ, SUSAN EMILY | 1651 | §103 | Final Rejection | 44d overdue | Pending | Jun 03, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial